Friday, July 10, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “qing” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 138
Total indexed 20,548
Sponsors 1,771

Quick answer

Showing 138 pipeline programs matching "qing" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

138 results for “qing” Back to intelligence hub

Search results

Page 2 of 6
  1. 100 mg PRAX-944

    Chongqing Precision Biotech Co., Ltd

    Essential Tremor

    phase 2 small molecule completed

    1 trial
  2. 30mg PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Onset Seizure

    phase 2 small molecule active

    1 trial
  3. 60 mg PRAX-114 or 40 mg PRAX-114

    Chongqing Precision Biotech Co., Ltd

    Post-traumatic Stress Disorder

    phase 2 small molecule terminated

    1 trial
  4. Atorvastatin Oral Tablet

    Chongqing Precision Biotech Co., Ltd

    Mild Cognitive Impairment

    phase 2 small molecule active

    1 trial
  5. BCMA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    2 trials
  6. BCMA targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 mab active

    1 trial
  7. CD123 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials
  8. CD123 targeted CAR-NK cells

    Chongqing Precision Biotech Co., Ltd

    Acute Myeloid Leukemia

    phase 2 mab active

    1 trial
  9. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Autoimmune Diseases

    phase 2 mab active

    1 trial
  10. CD19 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia

    phase 2 mab active

    2 trials
  11. CD19 and CD22 targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Leukemia, B-cell

    phase 2 mab active

    2 trials
  12. CD19 and CD22 targeted prime CAR- T cells

    Chongqing Precision Biotech Co., Ltd

    B Cell Lymphoma

    phase 2 mab active

    1 trial
  13. CD19 and CD22 targeted prime CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    B-ALL

    phase 2 mab active

    1 trial
  14. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Solid Tumor

    phase 2 mab active

    1 trial
  15. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 2 mab active

    3 trials
  16. Gemcitabine

    Chongqing Precision Biotech Co., Ltd

    Pancreatic Cancer, Adult

    phase 2 small molecule terminated

    1 trial
  17. Lifei Qingchang Granules

    The First People's Hospital of Lianyungang

    Bronchiectasis

    phase 2 small molecule active

    1 trial
  18. Melphalan flufenamide (Melflufen)

    Chongqing Precision Biotech Co., Ltd

    Multiple Myeloma

    phase 2 small molecule completed

    1 trial
  19. NEO-201 in combination with pembrolizumab

    Chongqing Precision Biotech Co., Ltd

    Non Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial
  20. NPC-1C/NEO-102

    Chongqing Precision Biotech Co., Ltd

    Metastatic Pancreatic Cancer

    phase 2 small molecule completed

    1 trial
  21. NY-ESO-1(TCR Affinity Enhancing Specific T cell Therapy)

    Chongqing Precision Biotech Co., Ltd

    Soft Tissue Sarcoma

    phase 2 mab active

    1 trial
  22. OPM-101

    Chongqing Precision Biotech Co., Ltd

    Advanced Melanoma

    phase 2 small molecule active

    1 trial
  23. PBCAR20A

    Chongqing Precision Biotech Co., Ltd

    Non-Hodgkin's Lymphoma, Relapsed

    phase 2 gene therapy completed

    1 trial
  24. PBGENE-DMD (IV)

    Chongqing Precision Biotech Co., Ltd

    Duchenne Muscular Dystrophy With Mutations Amenable to PBGENE-DMD

    phase 2 mab active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.